Skip to main content

Table 2 Endpoints from study investigating EPA/placebo vs. EPA/celecoxib by Cerchietti et al [30]

From: A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

 

Fish oil/placebo

Fish oil/celecoxib

pvalues

Grip strength

1.16 (0.3)

3.12 (0.95)*

P = 0.002

Body weight (Kg)

-1.4 (0.84)

1.5 (1.2)*

P = 0.05

LBM (Kg)

-0.6 (0.67)

0.4 (0.6)

NS

Fat Mass (Kg)

-0.6 (0.8)

1.2 (0.64)

NS

  1. LBM = Lean body mass. Data are recorded mean with SE in parentheses.*P < 0.02 compared to their respective baseline value.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us